Biogen (NASDAQ:BIIB) Given New $197.00 Price Target at The Goldman Sachs Group
Biogen (NASDAQ:BIIB – Get Free Report) had its target price decreased by equities researchers at The Goldman Sachs Group from $219.00 to $197.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 64.84% […]
Biogen (NASDAQ:BIIB – Get Free Report) had its target price decreased by equities researchers at The Goldman Sachs Group from $219.00 to $197.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 64.84% […]